Show simple item record

dc.contributor.authorSpencer, Thomas
dc.contributor.authorBiederman, Joseph
dc.contributor.authorWilens, Timothy
dc.contributor.authorPrince, Jeffry
dc.contributor.authorHatch, Mary
dc.contributor.authorJones, Janice
dc.contributor.authorHarding, Margaret
dc.contributor.authorFaraone, Stephen V.
dc.contributor.authorSeidman, Larry
dc.date.accessioned2021-07-30T15:14:05Z
dc.date.available2021-07-30T15:14:05Z
dc.date.issued1998-05
dc.identifier.issn0002-953X
dc.identifier.eissn1535-7228
dc.identifier.doi10.1176/ajp.155.5.693
dc.identifier.pii10.1176/ajp.155.5.693
dc.identifier.urihttp://hdl.handle.net/20.500.12648/2015
dc.description.abstractObjective: The authors assessed the experimental noradrenergic compound tomoxetine as an alternative treatment for adult attention deficit hyperactivity disorder (ADHD). Method: They conducted a double-blind, placebo-controlled, crossover study of tomoxetine in 22 adults with well-characterized ADHD. Results: Treatment with tomoxetine at an average oral dose of 76 mg/day was well tolerated. Drug-specific improvement in ADHD symptoms was highly significant overall and sufficiently robust to be detectable in a parallel-groups comparison restricted to the first 3 weeks of the protocol. Eleven of 21 patients showed improvement after receiving tomoxetine, compared with only two of 21 patients who improved after receiving placebo. Significant tomoxetine-associated improvement was noted on neuropsychological measures of inhibitory capacity from Stroop tests. Conclusions: This preliminary study showed that tomoxetine was effective in treating adult ADHD and was well tolerated. These promising results provide support for further studies of tomoxetine over an extended period of treatment.en_US
dc.language.isoenen_US
dc.publisherAmerican Psychiatric Association Publishingen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectPsychiatry and Mental healthen_US
dc.titleEffectiveness and Tolerability of Tomoxetine in Adults With Attention Deficit Hyperactivity Disorderen_US
dc.typeArticleen_US
dc.source.journaltitleAmerican Journal of Psychiatryen_US
dc.source.volume155
dc.source.issue5
dc.source.beginpage693
dc.source.endpage695
dc.description.versionAMen_US
refterms.dateFOA1999-05-30T00:00:00Z
dc.description.institutionUpstate Medical Universityen_US
dc.description.departmentPsychiatryen_US
dc.description.degreelevelN/Aen_US


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International